

| Drug | Schedule |
|---|----------|
| 2,5-Dimethoxyamphetamine (7396). | I |
| JWH-398 (7398) | I |
| 2,5-Dimethoxy-4-ethylamphetamine (7399). | I |
| 3,4-Methylenedioxyamphetamine (7400). | I |
| 5-Methoxy-3,4-methylenedioxyamphetamine (7401). | I |
| N-Hydroxy-3,4-methylenedioxyamphetamine (7402). | I |
| 3,4-Methylenedioxy-N-ethylamphetamine (7404). | I |
| 3,4-Methylenedioxyamphetamine (7405). | I |
| 4-Methoxyamphetamine (7411) ... | I |
| 5-Methoxy-N,N-dimethyltryptamine (7431). | I |
| Alpha-methyltryptamine (7432) | I |
| Bufotenine (7433) | I |
| Diethyltryptamine (7434) | I |
| Dimethyltryptamine (7435) | I |
| Psilocybin (7437) | I |
| Psilocyn (7438) | I |
| 5-Methoxy-N,N-diisopropyltryptamine (7439). | I |
| N-Ethyl-1-phenylcyclohexylamine (7455). | I |
| N-Benzylpiperazine (7493) | I |
| 2C-D (7508) | I |
| 2C-E (7509) | I |
| 2C-H (7517) | I |
| 2C-I (7518) | I |
| 2C-C (7519) | I |
| 2C-N (7521) | I |
| 2C-P (7524) | I |
| 2C-T-4 (7532) | I |
| MDPV (7535) | I |
| Methylone (7540) | I |
| AM-694 (7694) | I |
| Desmorphine (9055) | I |
| Dihydromorphine (9145) | I |
| Heroin (9200) | I |
| Morphine-N-oxide (9307) | I |
| Normorphine (9313) | I |
| Tilidine (9750) | I |
| Amphetamine (1100) | II |
| Methamphetamine (1105) | II |
| Lisdexamfetamine (1205) | II |
| Pentobarbital (2270) | II |
| Phencyclidine (7471) | II |
| Phenylacetone (8501) | II |
| Codeine (9050) | II |
| Dihydrocodeine (9120) | II |
| Oxycodone (9143) | II |
| Hydromorphone (9150) | II |
| Hydrocodone (9193) | II |
| Levomethorphan (9210) | II |
| Meperidine (9230) | II |
| Meperidine intermediate-B (9233) | II |
| Methadone (9250) | II |
| Dextropropoxyphene, bulk (non-dosage forms) (9273). | II |
| Morphine (9300) | II |
| Thebaine (9333) | II |
| Oxymorphone (9652) | II |
| Sufentanil (9740) | II |
| Fentanyl (9801) | II |

The company plans to manufacture reference standards for distribution to their research and forensics customers. In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic tetrahydrocannabinol (7370). No other activity for this drug code is authorized for this registration.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than March 11, 2014.

Dated: December 31, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2014-00200 Filed 1-9-14; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances Notice of Application Cody Laboratories, Inc.

Pursuant to 21 CFR 1301.33(a), this is notice that on June 12, 2013, Cody Laboratories, Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug | Schedule |
|---|----------|
| Dihydromorphine (9145) | I |
| Amphetamine (1100) | II |
| Methamphetamine (1105) | II |
| Methylphenidate (1724) | II |
| Amobarbital (2125) | II |
| Pentobarbital (2270) | II |
| Secobarbital (2315) | II |
| 4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333). | II |
| Phenylacetone (8501) | II |
| Cocaine (9041) | II |
| Codeine (9050) | II |
| Dihydrocodeine (9120) | II |
| Oxycodone (9143) | II |
| Hydromorphone (9150) | II |
| Diphenoxylate (9170) | II |

| Drug | Schedule |
|---------------------------|----------|
| Ecgonine (9180) | II |
| Hydrocodone (9193) | II |
| Meperidine (9230) | II |
| Methadone (9250) | II |
| Morphine (9300) | II |
| Thebaine (9333) | II |
| Oxymorphone (9652) | II |
| Alfentanil (9737) | II |
| Remifentanil (9739) | II |
| Sufentanil (9740) | II |
| Tapentadol (9780) | II |
| Fentanyl (9801) | II |

The company plans on manufacturing the listed controlled substances in bulk for sale to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODW), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than March 11, 2014.

Dated: December 31, 2013.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2014-00204 Filed 1-9-14; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration; Organix, Inc.

By Notice dated August 20, 2013, and published in the **Federal Register** on August 26, 2013, 78 FR 52801, Organix, Inc., 240 Salem Street, Woburn, Massachusetts 01801, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug | Schedule |
|------------------------------------|----------|
| Marihuana (7360) | I |
| Tetrahydrocannabinols (7370) | I |
| Psilocybin (7437) | I |
| Psilocyn (7438) | I |

The company plans to synthesize small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Organix, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time.

DEA has investigated Organix, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.

Dated: December 31, 2013.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2014-00198 Filed 1-9-14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Office of Justice Programs

[OMB Number 1121-0095]

Agency Information Collection Activities: Proposed Collection; Comments Requested 2013 National Survey of Indigent Defense Systems

ACTION: 60-day notice.

The Department of Justice (DOJ), Office of Justice Programs, Bureau of Justice Statistics will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collected is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for "sixty days" until March 11, 2014. This process is conducted in accordance with 5 CFR 1320.10.

If you have comments especially the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Alexia Cooper, Statistician, Bureau of Justice Statistics, Office of Justice Programs, U.S. Department of Justice, 810 Seventh Street NW.,

Washington, DC 20531 (phone: 202-302-0582).

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Overview of this information collection:

(1) *Type of information collection:*

Reinstatement with change of a previously approved collection for which approval has expired

(2) *The title of the Form/Collection:* 2013 National Survey of Indigent Defense Systems

(3) *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* OMB Control #1121-0095, Bureau of Justice Statistics, Office of Justice Programs, United States Department of Justice.

(4) *Affected public who will be asked to respond, as well as a brief abstract:* Primary: State and county based indigent defense systems. Staff in state and county based indigent defense systems will be asked to provide information on the following: fiscal resources and expenditures; case-types and caseloads; personnel and compensation; processes for selecting the chief public defender or administrator; procedures for indigence determination; professional development opportunities; use of information technology; standards and guidelines; and boards or commissions. The Bureau of Justice Statistics plans to publish this information in reports and reference it when responding to queries from the U.S. Congress, Executive Office of the President, the U.S. Supreme

Court, state officials, international organizations, researchers, students, the media, and others interested in criminal justices statistics.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* 1,574 respondents at 3.0 hours each. Respondents have the option to provide responses using either paper or web-based questionnaires. The burden estimate is based on feedback from respondents gathered during pilot testing.

(6) *An estimate of the total public burden (in hours) associated with the collection:* There is an estimated 4,694 annual total burden hours associated with this collection.

If additional information is required contact: Jerri Murray, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Avenue, 145 N Street NE., Room 3W-1407B, Washington, DC 20530.

Dated: January 7, 2014.

Jerri Murray,

Department Clearance Officer for PRA, Department of Justice.

[FR Doc. 2014-00218 Filed 1-9-14; 8:45 am]

BILLING CODE 4410-18-P

DEPARTMENT OF LABOR

Employment and Training Administration

[TA-W-82,663]

Belden, Inc.; Including On-Site Leased Workers From Adecco Horseheads, New York; Notice of Revised Determination on Reconsideration

The initial investigation, instituted on April 18, 2013, resulted in a negative determination, issued on June 14, 2013, that was based on the Department's finding of no shift in production by Belden, Inc., Horseheads, New York (subject firm) to a foreign country and neither subject firm nor customer imports. The Department's Notice of negative determination was published in the **Federal Register** on July 2, 2013 (78 FR 39776).

Workers of the subject firm are engaged in activity related to the production and assembly of coaxial cable connectors and parts, and are not separately identifiable by article produced. The worker group includes on-site leased workers from Adecco.

During the reconsideration investigation, the Department confirmed previously-submitted information and